What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial

European Archives of Psychiatry and Clinical Neuroscience

Volumn 265, Issue 2, 2015, Pages 107-116

  Schennach, Rebecca ^a,p   Riedel, Michael ^a,b   Obermeier, Michael ^a,q   Spellmann, Ilja ^a,r   Musil, Richard ^a   Jäger, Markus ^a   Schmauss, Max ^c   Laux, Gerd ^d   Pfeiffer, Herbert ^e   Naber, Dieter ^f   Schmidt, Lutz G ^g   Gaebel, Wolfgang ^h   Klosterkötter, Joachim ⁱ   Heuser, Isabella ^j   Maier, Wolfgang ^k   Lemke, Matthias R ^l   Rüther, Eckart ^m   Klingberg, Stefan ⁿ   Gastpar, Markus ^o   Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Vinzenz von Paul Hospital   (Germany)

^c District Hospital Augsburg   (Germany)

^d Inn Salzach Hospital   (Germany)

^e KLINIKUM MÜNCHEN OST   (Germany)

^f UNIVERSITY OF HAMBURG   (Germany)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY OF BONN   (Germany)

^l Alsterdorf Hospital   (Germany)

^m UNIVERSITY OF GÖTTINGEN   (Germany)

ⁿ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^o UNIVERSITY OF DUISBURG ESSEN   (Germany)

^p Schoen Clinic Roseneck   (Germany)

^q GKM   (Germany)

^r District Hospital Kaufbeuren   (Germany)

more..

Author keywords

Outcome; Remission; Residual symptoms; Schizophrenia

Indexed keywords

ADULT; ARTICLE; ATTENTION DISTURBANCE; BLUNTED AFFECT; BORDERLINE STATE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONCEPTUAL DISORGANIZATION; CONTROLLED STUDY; DELUSION; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORIENTATION; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR RETARDATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RELAPSE; REMISSION; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SCHIZOPHRENIA SPECTRUM DISORDER; SYMPTOM ASSESSMENT; WITHDRAWAL SYNDROME; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FOLLOW UP; MENTAL DISEASE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; RECURRENT DISEASE; RETROSPECTIVE STUDY;

NEUROLEPTIC AGENT;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPATHOLOGY; PSYCHOTIC DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84925465063     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-014-0528-2     Document Type: Article

References (40)

1. Nasrallah HA, Lasser R (2006) Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 20:57–61
2. Schennach-Wolff R, Moller HJ, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Riedel M (2010) A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. Pharmacopsychiatry 43:245–251
3. Karow A, Naber D, Lambert M, Moritz S (2011) Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry (In Press)
4. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ (2010) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 40:41–50
5. Gross G, Huber G (2008) Psychopathology of schizophrenia and brain imaging. Fortschr Neurol Psychiatr 76(Suppl 1):S49–S56
6. Paykel ES (1998) Remission and residual symptomatology in major depression. Psychopathology 31:5–14
7. Wolwer W, Buchkremer G, Hafner H, Klosterkotter J, Moller HJ, Maier W, Gaebel W (2003) German research network on schizophrenia-bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci 253:321–329
8. Jager M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Kuhn KU, Lemke MR, Ruther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Moller HJ (2007) Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257:47–53
9. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
10. Cording C (1998) Conceptual aspects in development and implementation of basic psychiatric documentation. Psychiatr Prax 25:175–178
11. Kay SR, Opler LA, Lindenmayer JP (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23:99–110
12. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100
13. Andreasen NC, Carpenter WT, Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449
14. Seemüller F, Riedel M, Obermeier M, Golstein-Müller B, Adli M, Bauer M, Kronmuller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Möller H-J (2011) Clinical description and 1-year persistence of residual symptoms in a large naturalistic sample of remitted depressed inpatients (Unpublished Work)
15. R Development Core Team (2008) A language and environment for statistical computing. Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org
16. Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D (2006) Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 86:300–308
17. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D (2010) Remission in schizophrenia: its validity, frequency, predictors and patients’ perspective 5 years after. Dialog Clin Neurosci (in press)
18. Beitinger R, Lin J, Kissling W, Leucht S (2008) Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry 32:1643–1651
19. David A, Van OJ, Jones P, Harvey I, Foerster A, Fahy T (1995) Insight and psychotic illness. Cross-sectional and longitudinal associations. Br J Psychiatry 167:621–628
20. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA (2009) Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 35:336–346
21. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T (2006) Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res 40:738–745
22. Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A III, Carson WH, Swyzen W (2007) Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 95:143–150
23. Alptekin K, Erkoc S, Gogus AK, Kultur S, Mete L, Ucok A, Yazici KM (2005) Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up. Psychiatry Res 135:103–111
24. Saravanan B, Jacob KS, Johnson S, Prince M, Bhugra D, David AS (2010) Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. Br J Psychiatry 196:454–459
25. Bora E, Gokcen S, Kayahan B, Veznedaroglu B (2008) Deficits of social-cognitive and social-perceptual aspects of theory of mind in remitted patients with schizophrenia: effect of residual symptoms. J Nerv Ment Dis 196:95–99
26. Alenius M, Hammarlund-Udenaes M, Hartvig P, Sundquist S, Lindstrom L (2009) Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission. Compr Psychiatry 50:453–462
27. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB (1998) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:694–700
28. Fava M (2006) Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol 20:29–34
29. Chabungbam G, Avasthi A, Sharan P (2007) Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci 61:587–593
30. Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M (2006) Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 26:571–578
31. Tandon R, Nasrallah HA, Keshavan MS (2009) Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res 110:1–23
32. Moller HJ, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R (2010) The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur Arch Psychiatry Clin Neurosci 260:367–384
33. Ribeiro SC, Tandon R, Ricoy R, Mazzara C, Craig KA, Greden JF (1992) Clinical predictors of 1-year outcome in schizophrenia. Psychopathology 25:331–334
34. Chang WC, Hui CL, Tang JY, Wong GH, Lam MM, Chan SK, Chen EY (2011) Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res 133:22–28
35. Hovington CL, Bodnar M, Joober R, Malla AK, Lepage M (2012) Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 12:224. doi:10.1186/1471-244X-12-224.:224-12
36. Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS (2013) Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 23:196–204
37. Leifker FR, Bowie CR, Harvey PD (2009) Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. Schizophr Res 115:82–87
38. Henmi Y (1993) Prodromal symptoms of relapse in schizophrenic outpatients: retrospective and prospective study. Jpn J Psychiatry Neurol 47:753–775
39. Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, Judd LL, Jeste DV (1999) Depressive symptoms in schizophrenia. Am J Psychiatry 156:1736–1743
40. Chan GW, Ungvari GS, Shek DT, Leung Dagger JJ (2003) Hospital and community-based care for patients with chronic schizophrenia in Hong Kong–quality of life and its correlates. Soc Psychiatry Psychiatr Epidemiol 38:196–203